

Review Article



Catheter Ablation of Long-standing Persistent Atrial Fibrillation: a Reckless Challenge or a Way to Real Cure?

Hui-Nam Pak , MD, PhD

Division of Cardiology, Department of Internal Medicine, Yonsei University Health System, Seoul, Korea

 OPEN ACCESS

Received: Nov 15, 2018

Accepted: Dec 10, 2018

Correspondence to

Hui-Nam Pak, MD, PhD

Division of Cardiology, Department of Internal Medicine, Yonsei University Health System, 50-1, Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.
E-mail: hnpak@yuhs.ac

Copyright © 2019. The Korean Society of Cardiology

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORCID iDs

Hui-Nam Pak 

<https://orcid.org/0000-0002-3256-3620>

Funding

This work was supported by a grant (HI18CO070) from the Korea Health 21 R&D Project, Ministry of Health and Welfare and a grant (NRF-2017R1A2B4003983) from the Basic Science Research Program run by the National Research Foundation of Korea (NRF), which is funded by the Ministry of Science, ICT & Future Planning (MSIP).

Conflict of Interest

The author has no financial conflicts of interest.

ABSTRACT

Long-standing persistent atrial fibrillation (L-PeAF) is a category in which rhythm control is attempted while atrial fibrillation (AF) is maintained for more than 1 year. Because AF is a progressive disease and L-PeAF accompanies significant electrical and structural remodeling of atria, it is difficult to restore and maintain sinus rhythm in patients with L-PeAF. Nonetheless, the rhythm outcome is being increasingly improved by the development of sophisticated mapping devices, highly efficient catheters, and evidence-based ablation strategies, and the rational choice of patient selection criteria. This review discusses the evolution of the rhythm control outcome of L-PeAF and its future direction of development.

Keywords: Persistent atrial fibrillation; Catheter ablation; Pulmonary veins

INTRODUCTION

Radiofrequency catheter ablation (RFCA) is an effective rhythm control strategy for patients with atrial fibrillation (AF), and it has become a standard procedure for anti-arrhythmic drugs (AADs)-resistant AF in current guidelines for AF management.¹⁾ Recently, it was reported that AF catheter ablation reduced mortality in patients with heart failure by about 40%,²⁾ and incidence of ischemic stroke³⁾ and dementia⁴⁾ compared to medical therapy. Nevertheless, AF is a progressive disease and continues to have a constant rate of recurrence after ablation. The main target of AF catheter ablation is the pulmonary veins (PVs), and durable circumferential pulmonary vein isolation (CPVI) is the cornerstone of this procedure.⁵⁾ However, AF catheter ablation remains challenging in patients with persistent atrial fibrillation (PeAF) and long-standing persistent atrial fibrillation (L-PeAF).⁶⁾ As evidenced by a substantially high recurrence rate, CPVI alone has been considered insufficient in catheter ablation for PeAF.⁷⁾ To overcome this limitation, various ablation strategies have been attempted, including additional linear ablation, complex fractionate atrial electrogram (CFAE) guided ablation, right atrial (RA) ablation, non-PV foci ablation, and rotor ablation. Despite the various ablation strategies for PeAF, the success rate of a single procedure has ranged between 20 and 60%.⁶⁾ Moreover, Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR-AF) II trial documented no incremental benefit of additional extra-PV-left atrial (LA) ablation compared to CPVI alone in patients with PeAF.⁸⁾ In contrast, long-term AF control

rate becomes 72–79% with or without AAD by performing 1.3–2.3 additional procedures for recurred AF patients.⁹⁾ Although RFCA for L-PeAF significantly reduces AF burden, this procedure still has limitations even when it is performed with current technology at world-class, highly experienced institutions. Here, the mechanism and limitations of RFCA for PeAF are reviewed based on the recent clinical studies.

PATHOPHYSIOLOGY OF PERSISTENT ATRIAL FIBRILLATION

AF is a progressive disease and the mechanism for generation of AF is not yet fully understood.¹⁰⁾¹¹⁾ Coumel¹²⁾¹³⁾ suggested that trigger factors or trigger foci initiate AF, and an arrhythmic substrate leads to its persistence. It is known that 70–90% of AF triggers exist around PVs in patients with paroxysmal AF, but non-PV foci are more common in those with PeAF.¹⁴⁻¹⁶⁾ Generally, PV isolation at the level of PV antrum is the mainstay of catheter ablation for AF,¹⁷⁻¹⁹⁾ but PV isolation may not be enough for PeAF with multiple non-PV triggers. Verma et al.²⁰⁾ considered CFAE-guided ablation to be well-suited for non-PV substrate and trigger ablation, and Lemery et al.²¹⁾ found CFAE map to co-localize with cardiac autonomic ganglionate plexi detected by nerve stimulation. Another factor to consider in the mechanism of PeAF is AF progression and structural remodeling. AF is a progressive disease associated with increased atrial size,²²⁾ histological change,²³⁾ higher number of co-morbid factors,²⁴⁾ and more frequent overall cardiovascular events.²⁵⁾ Significant structural remodeling makes atria susceptible to a continuous wave break and the maintenance of fibrillation by increasing critical mass.²⁶⁾ Anti-fibrillatory effects of critical mass reduction have been proved with radiofrequency (RF) energy delivery,²⁵⁾²⁷⁾ cut and sew operation,²⁸⁾ pharmacologic effect,²⁶⁾ and pacing effects²⁹⁾ in ex-vivo and in vivo animal model as well as human heart models.³⁰⁾³¹⁾ Therefore, the reduction of atrial critical mass can be one potential anti-arrhythmic mechanism of linear AF catheter ablation for PeAF patients with significant atrial remodeling.

WHAT DID WE LEARN IN THE PAST 10 YEARS?

Over the past 10 years, we have learned that AF is a chronic progressive disease and not curable by catheter ablation. Although the development of efficient ablation catheters and sophisticated mapping systems has improved the outcome of AF ablation, the long-term recurrence rate is still close to 50%. Nonetheless, we were able to evaluate the results of our procedure because we performed consistent and steady rhythm monitoring based on the 2012 Heart Rhythm Society/European Heart Rhythm Association/European Cardiac Arrhythmia Society expert consensus statement guidelines³²⁾ in Yonsei AF ablation cohort (ClinicalTrials.gov Identifier: NCT02138695). Among the prognostic factors associated with the patient's characteristics, a young female,³³⁾ high pericardial fat volume,³⁴⁾ being overweight,³⁵⁾ longer PR interval,³⁶⁾ and high LA pressure³⁷⁾ were factors associated with a higher clinical recurrence rate after AF ablation. In particular, the outcome of catheter ablation in patients with L-PeAF was affected by the pre-ablation external cardioversion energy³⁸⁾ or specific genetic factors, such as the *ZFHX3* genetic trait.³⁹⁾ Regarding the intra-procedural factors, appropriate parasympathetic modulation by AF ablation measured by the heart rate variability (HRV)⁴⁰⁾ and the absence of post-ablation extra-PV triggers⁴¹⁾

were related to a good rhythm outcome after AF ablation. Among the patients with PeAF, recurrence was lower in those with a posterior wall isolation in the de novo ablation.⁴²⁾ However, for the patients who improved from PeAF to paroxysmal AF after using antiarrhythmic drugs, additional linear ablation after the CPVI did not affect the outcome.⁴³⁾ Among the patients with L-PeAF, additional CFAE ablation after the CPVI plus linear ablation did not improve the rhythm outcome.⁴⁴⁾

ROLE OF CIRCUMFERENTIAL PULMONARY VEIN ISOLATION IN PERSISTENT ATRIAL FIBRILLATION

In 1993, Schwartz initially described a catheter-based technique for linear ablation of PeAF (AHA abstract, *Circulation*.1993;90:335). In 1998, Haïssaguerre et al.¹⁷⁾ reported the importance of PV triggers elimination in patients with paroxysmal AF. Afterward, catheter ablation of AF, a much less invasive procedure compared to the maze operation, was accepted as an effective rhythm control strategy. The efficacy of CPVI has been well established and considered to be the cornerstone of RFCA for AF.⁴⁵⁾ Verma et al.⁸⁾ proved equivalent efficacy of CPVI compared to additional linear ablation or CFAE-guided ablation in randomized clinical trial; STAR AF II. In spite of this clinical results, in patients with L-PeAF, it is associated with a high recurrence rate (60% in a year) due to extensive atrial substrate remodeling and atrial dilatation.¹⁴⁾²⁹⁾ However, it still remains the most important step of ablation for PeAF for the following reasons: 1) AF triggers frequently arise from PVs⁴⁶⁾; 2) cardiac autonomic nerves reach the heart mainly along the PV antral area¹⁴⁾⁴⁷⁾⁴⁸⁾; and 3) CPVI itself reduces about 15–17% of LA critical mass. In other words, CPVI is effective in elimination of PV triggers,⁴⁹⁾⁵⁰⁾ cardiac autonomic denervation,⁵¹⁾ and substrate modification in both paroxysmal AF and PeAF.

STEPWISE APPROACH FOR PERSISTENT ATRIAL FIBRILLATION ABLATION: LINEAR ABLATION

A stepwise approach of adding linear ablations to CPVI has been known to be an effective AF substrate modification.⁵²⁻⁵⁴⁾ This stepwise AF ablation was first introduced by Haïssaguerre et al.⁵²⁾ and is an important strategy to terminate PeAF or macro-reentrant atypical atrial tachycardias. The benefit of linear ablation in addition to CPVI has been reported in multiple clinical studies,⁹⁾⁵³⁾⁵⁵⁻⁵⁷⁾ and a meta-analysis (odds ratio, 0.22; 95% confidence interval, 0.1–0.49; $p < 0.001$).⁵⁸⁾ As increments of linear ablation lesions, the organization of AF into atrial tachycardia might be a sign suggesting a stepwise reduction of atrial critical mass during RFCA. However, there are several limitations in linear ablation in addition to CPVI: 1) the achievement of complete bidirectional block of linear ablation is sometimes very difficult; 2) incomplete block or reconnection of linear ablation is a major reason for recurrence and aggravates macro-reentrant tachycardia; 3) confirming bidirectional block of linear ablation by differential pacing maneuver⁵⁹⁻⁶¹⁾ is not always accurate; and 4) excessive ablation to achieve bidirectional block may increase the risk of collateral damage. In our institution, the bidirectional block rates for roof line and anterior line were 90% and 68%, respectively. During the redo-ablation procedure for recurred patients, previously blocked roof line and anterior line were maintained in only 67% and 37%, respectively.⁴²⁾

COMPLEX FRACTIONATED ATRIAL ELECTROGRAM GUIDED ABLATION

CFAE was initially introduced by Konings et al.⁶²⁾ as an electrogram showing high frequency and irregularity that were recorded by high density mapping of AF at right atrium. Afterward, Nademanee et al.⁶³⁾ reported that CFAE area recorded by a bipolar catheter represented an electrophysiologic substrate of AF and an ideal target for ablation to eliminate AF. Clinically, CFAE is known to play a role in maintaining AF,⁶⁴⁾⁶⁵⁾ co-localize with the autonomic ganglionate plexi,²¹⁾ and act as a target for AF catheter ablation.⁶³⁾⁶⁵⁾ However, CFAE-guided ablation has its limitations: it is somewhat subjective and is based on uncertain pathophysiology. The mechanism of CFAE is still controversial as CFAE can be generated by anatomical factors (such as complex anisotropy),⁵²⁾⁶³⁾⁶⁶⁾⁶⁷⁾ histologic factors (focal myocardial fibrotic scar),⁶⁸⁾ or functional reentries.⁶⁹⁻⁷²⁾ We previously reported that CFAE is primarily located in the area of low voltage and conduction velocity, surrounded by high voltage areas,⁷³⁾ and that CFAE cycle length is longer in patients with remodeled atrium.⁷⁴⁾ However, CFAE includes both the active driver of AF and passive wave breakers, and extensive CFAE-guided AF ablation has the risk of unnecessary cardiac tissue damage. Oral et al.⁷⁵⁾ reported that an additional ablation of CFAE after CPVI did not improve clinical outcome of RFCA. In a recent meta-analysis, CFAE ablation in addition to CPVI did not show significant reduction of clinical recurrence rate compared to that with CPVI alone.⁵⁸⁾

ABLATIONS FOR LEFT ATRIAL APPENDAGE, RIGHT ATRIAL ABLATION, GANGLIONATE PLEXI, OR ROTOR

Di Biase et al.⁷⁶⁾ reported that LA appendage was an arrhythmogenic structure and that electrical isolation of LA appendage reduced AF recurrence after catheter ablation. LA appendage has highly bumpy surface vulnerable to wave break⁷⁷⁾ and is co-localized with ligament of Marshall and ganglionate plexus. However, the risk of stroke should be considered after LA appendage isolation, because intra-cardiac thrombus is commonly formed in LA appendage.

During the stepwise approach in PeAF ablation, it is often necessary to ablate RA in addition to LA, because previous biatrial mapping has demonstrated multiple biatrial sources of tachycardia in human AF.⁷⁸⁾⁷⁹⁾ In fact, Kim⁸⁰⁾ reported over 50% chance of AF termination by additional RA CFAE ablation when LA ablation alone was not successful in patients with L-PeAF. Although random study on routine RA CFAE ablation did not show incremental efficacy compared with LA ablation,⁸¹⁾ RA inter-caval linear ablation and superior vena cava (SVC) isolation improved clinical outcome of PeAF and L-PeAF ablation.⁸²⁾ Kang et al.⁴⁰⁾ reported that linear ablation from SVC to RA septum produced autonomic denervation effects on post-procedural HRV and better clinical outcome in patients with paroxysmal AF, but not in those with PeAF.

Narayan et al.⁸³⁾ recorded AF activation with 64-pole basket catheters in both atria, and demonstrated the presence of electrical rotors and repetitive focal beats during AF. Although their definition of rotor was not the same to that of classical basic electrophysiology (unexcited but eminently excitable spiral wave core),⁸⁴⁾⁸⁵⁾ focal impulse and rotor modulation was reported to improved clinical outcome.⁸³⁾⁸⁶⁾ However, clinical data from other groups are controversial so far.⁸⁷⁾

SURGICAL ATRIAL FIBRILLATION ABLATION

The recent European Society of Cardiology guidelines on AF managements⁸⁸⁾ recommend surgical ablation for the following patients; 1) symptomatic AF patients undergoing cardiac surgery (IIA–A); 2) asymptomatic AF patients undergoing cardiac surgery in whom the ablation can be performed with minimal risk (IIB–C); and 3) patients with stand-alone AF who have failed catheter ablation and in whom minimally invasive surgical ablation is feasible (IIB–C). Surgical maze procedure has some benefits compared with catheter ablation, such as the excision of LA appendage, ganglionated plexi ablation, and relatively feasible epicardial approach. Recently, a number of institutions reported that a minimally invasive AF surgery using thoracoscopic surgical ablation combined with ganglionated plexi ablation was able to provide AF free survival in over 80% of patients during the follow-up duration of 12 months.^{49)89–91)} Boersma et al.⁹²⁾ reported superior clinical outcome of surgical ablation than catheter ablation, but a procedure related adverse events rate was significantly higher in surgical ablation (34.4%) than catheter ablation (15.9%). Therefore, highly selected patients with less amendable factors related to AF may be good candidates of AF surgery.⁹³⁾ However, recent randomized controlled trial failed to show superior efficacy of minimally invasive thoracoscopic PV isolation with LA appendage ligation compared to catheter ablation in spite of significantly higher complication rate.⁹⁴⁾

BALANCED SUBSTRATE MODIFICATION WITH LIMITED TISSUE DAMAGE

Although CPVI alone may not be enough in patients with PeAF, more extra-PV LA ablations may generate more scar⁹⁵⁾ and increase the risk of complication. Gibson et al.⁹⁶⁾ reported that pulmonary hypertension after catheter ablation was detected in 1.4% of patients without PV stenosis, in association with severe LA scarring, small LA dimension (≤ 45 mm), high LA pressure, diabetes and obstructive sleep apnea. The Delayed Enhancement-magnetic resonance imaging determinant of successful Catheter Ablation of Atrial Fibrillation (DECAAF) study showed poor clinical outcome after AF ablation in patients with extensive atrial scar.⁹⁷⁾ Shim et al.⁹⁸⁾ reported that long duration of RF ablation was an independent predictor of AF recurrence in patients with PeAF. Park et al.³⁷⁾ demonstrated that high LA pressure was associated with advanced LA remodeling related to low LA compliance and more frequent clinical recurrence of AF after catheter ablation. Therefore, balanced substrate modification with limited tissue damage is mandatory to achieve better long-term clinical outcome, minimizing procedure related complication rate.

FUTURE DIRECTIONS FOR LONG-STANDING PERSISTENT ATRIAL FIBRILLATION ABLATION

In the last decade, there was an enormous progress in AF ablation skill, technique, mapping system, and catheter design. Although there is no argument that appropriate AF catheter ablation reduces AF burden significantly, a recurrence rate of AF is still substantial, especially in patients with L-PeAF. Therefore, more focused mapping and ablation of non-PV triggers might be the solution for better rhythm outcome of PeAF ablation rather than an empirical extra-PV LA ablations. It is now essential to also consider patient factors before procedure, including clinical characteristics, biomarkers or genetic factors.⁹⁹⁾¹⁰⁰⁾ As medical technology

continues to progress, computer simulation guided ablation utilizing patient-specific virtual AF modeling may enable operators to choose the best ablation design for each patient.^{101,102)} RF energy titration depending on patient characteristics and atrial wall thickness is another important issue to overcome. Better understanding about AF pathophysiology and early precise intervention may improve clinical outcome of AF management.

CONCLUSION

Elimination of triggers without an additional substrate modification may not be sufficient in patients with PeAF. However, current ablation techniques regarding substrate modification still have many limitations, and recurrence and atrial tissue damage are inevitable. Keeping in mind “more touch, more scar,” operators should generate most efficient substrate modification to achieve better long-term clinical outcome.

REFERENCES

1. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. *J Am Coll Cardiol* 2014;64:2246-80. [CROSSREF](#)
2. Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. *N Engl J Med* 2018;378:417-27. [PUBMED](#) | [CROSSREF](#)
3. Mansour M, Heist EK, Agarwal R, et al. Stroke and cardiovascular events after ablation or antiarrhythmic drugs for treatment of patients with atrial fibrillation. *Am J Cardiol* 2018;121:1192-9. [PUBMED](#) | [CROSSREF](#)
4. Bunch TJ, Crandall BG, Weiss JP, et al. Patients treated with catheter ablation for atrial fibrillation have long-term rates of death, stroke, and dementia similar to patients without atrial fibrillation. *J Cardiovasc Electrophysiol* 2011;22:839-45. [PUBMED](#) | [CROSSREF](#)
5. Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. *Europace* 2012;14:528-606. [PUBMED](#) | [CROSSREF](#)
6. Brooks AG, Stiles MK, Laborderie J, et al. Outcomes of long-standing persistent atrial fibrillation ablation: a systematic review. *Heart Rhythm* 2010;7:835-46. [PUBMED](#) | [CROSSREF](#)
7. Tilz RR, Rillig A, Thum AM, et al. Catheter ablation of long-standing persistent atrial fibrillation: 5-year outcomes of the Hamburg Sequential Ablation Strategy. *J Am Coll Cardiol* 2012;60:1921-9. [PUBMED](#) | [CROSSREF](#)
8. Verma A, Jiang CY, Betts TR, et al. Approaches to catheter ablation for persistent atrial fibrillation. *N Engl J Med* 2015;372:1812-22. [PUBMED](#) | [CROSSREF](#)
9. Rostock T, Salukhe TV, Steven D, et al. Long-term single- and multiple-procedure outcome and predictors of success after catheter ablation for persistent atrial fibrillation. *Heart Rhythm* 2011;8:1391-7. [PUBMED](#) | [CROSSREF](#)
10. Wazni O, Wilkoff B, Saliba W. Catheter ablation for atrial fibrillation. *N Engl J Med* 2011;365:2296-304. [PUBMED](#) | [CROSSREF](#)
11. Inoue K, Kurotobi T, Kimura R, et al. Trigger-based mechanism of the persistence of atrial fibrillation and its impact on the efficacy of catheter ablation. *Circ Arrhythm Electrophysiol* 2012;5:295-301. [PUBMED](#) | [CROSSREF](#)
12. Coumel P Paroxysmal atrial fibrillation: a disorder of autonomic tone? *Eur Heart J* 1994;15 Suppl A:9-16. [PUBMED](#)

13. Coumel P. Autonomic influences in atrial tachyarrhythmias. *J Cardiovasc Electrophysiol* 1996;7:999-1007.
[PUBMED](#) | [CROSSREF](#)
14. Pak HN, Hwang C, Lim HE, Kim JW, Lee HS, Kim YH. Electroanatomic characteristics of atrial premature beats triggering atrial fibrillation in patients with persistent versus paroxysmal atrial fibrillation. *J Cardiovasc Electrophysiol* 2006;17:818-24.
[PUBMED](#) | [CROSSREF](#)
15. Oral H, Crawford T, Frederick M, et al. Inducibility of paroxysmal atrial fibrillation by isoproterenol and its relation to the mode of onset of atrial fibrillation. *J Cardiovasc Electrophysiol* 2008;19:466-70.
[PUBMED](#) | [CROSSREF](#)
16. Lee SH, Tai CT, Hsieh MH, et al. Predictors of non-pulmonary vein ectopic beats initiating paroxysmal atrial fibrillation: implication for catheter ablation. *J Am Coll Cardiol* 2005;46:1054-9.
[PUBMED](#) | [CROSSREF](#)
17. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. *N Engl J Med* 1998;339:659-66.
[PUBMED](#) | [CROSSREF](#)
18. Pappone C, Rosanio S, Oreto G, et al. Circumferential radiofrequency ablation of pulmonary vein ostia: a new anatomic approach for curing atrial fibrillation. *Circulation* 2000;102:2619-28.
[PUBMED](#) | [CROSSREF](#)
19. Kumar S, Kalman JM, Sutherland F, Spence SJ, Finch S, Sparks PB. Atrial fibrillation inducibility in the absence of structural heart disease or clinical atrial fibrillation: critical dependence on induction protocol, inducibility definition, and number of inductions. *Circ Arrhythm Electrophysiol* 2012;5:531-6.
[PUBMED](#) | [CROSSREF](#)
20. Verma A, Mantovan R, Macle L, et al. Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial. *Eur Heart J* 2010;31:1344-56.
[PUBMED](#) | [CROSSREF](#)
21. Lemery R, Birnie D, Tang AS, Green M, Gollob M. Feasibility study of endocardial mapping of ganglionated plexuses during catheter ablation of atrial fibrillation. *Heart Rhythm* 2006;3:387-96.
[PUBMED](#) | [CROSSREF](#)
22. Park JH, Joung B, Son NH, et al. The electroanatomical remodelling of the left atrium is related to CHADS2/CHA2DS2VASc score and events of stroke in patients with atrial fibrillation. *Europace* 2011;13:1541-9.
[PUBMED](#) | [CROSSREF](#)
23. Park JH, Pak HN, Lee S, Park HK, Seo JW, Chang BC. The clinical significance of the atrial subendocardial smooth muscle layer and cardiac myofibroblasts in human atrial tissue with valvular atrial fibrillation. *Cardiovasc Pathol* 2013;22:58-64.
[PUBMED](#) | [CROSSREF](#)
24. de Vos CB, Pisters R, Nieuwlaar R, et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. *J Am Coll Cardiol* 2010;55:725-31.
[PUBMED](#) | [CROSSREF](#)
25. De Vos CB, Breithardt G, Camm AJ, et al. Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of atrial fibrillation cohort: clinical correlates and the effect of rhythm-control therapy. *Am Heart J* 2012;163:887-93.
[PUBMED](#) | [CROSSREF](#)
26. West TC, Landa JF. Minimal mass required for induction of a sustained arrhythmia in isolated atrial segments. *Am J Physiol* 1962;202:232-6.
[PUBMED](#) | [CROSSREF](#)
27. Pak HN, Kim YH, Lim HE, et al. Role of the posterior papillary muscle and purkinje potentials in the mechanism of ventricular fibrillation in open chest dogs and Swine: effects of catheter ablation. *J Cardiovasc Electrophysiol* 2006;17:777-83.
[PUBMED](#) | [CROSSREF](#)
28. Pak HN, Kim GI, Lim HE, et al. Both Purkinje cells and left ventricular posteroseptal reentry contribute to the maintenance of ventricular fibrillation in open-chest dogs and swine: effects of catheter ablation and the ventricular cut-and-sew operation. *Circ J* 2008;72:1185-92.
[PUBMED](#) | [CROSSREF](#)
29. Pak HN, Okuyama Y, Oh YS, et al. Improvement of defibrillation efficacy with preshock synchronized pacing. *J Cardiovasc Electrophysiol* 2004;15:581-7.
[PUBMED](#) | [CROSSREF](#)
30. Wu TJ, Yashima M, Doshi R, et al. Relation between cellular repolarization characteristics and critical mass for human ventricular fibrillation. *J Cardiovasc Electrophysiol* 1999;10:1077-86.
[PUBMED](#) | [CROSSREF](#)

31. Choi JI, Ryu K, Park E, et al. Atrial activation time and pattern of linear triple-site vs. single-site atrial pacing after cardioversion in patients with atrial fibrillation. *Europace* 2010;12:508-16.
[PUBMED](#) | [CROSSREF](#)
32. Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) task force on catheter and surgical ablation of atrial fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. *Heart Rhythm* 2012;9:632-96.e21.
[PUBMED](#) | [CROSSREF](#)
33. Yu HT, Yang PS, Kim TH, et al. Poor rhythm outcome of catheter ablation for early-onset atrial fibrillation in women - mechanistic insight. *Circ J* 2018;82:2259-68.
[PUBMED](#) | [CROSSREF](#)
34. Kim TH, Park J, Park JK, et al. Pericardial fat volume is associated with clinical recurrence after catheter ablation for persistent atrial fibrillation, but not paroxysmal atrial fibrillation: an analysis of over 600-patients. *Int J Cardiol* 2014;176:841-6.
[PUBMED](#) | [CROSSREF](#)
35. Baek YS, Yang PS, Kim TH, et al. Delayed recurrence of atrial fibrillation 2 years after catheter ablation is associated with metabolic syndrome. *Int J Cardiol* 2016;223:276-81.
[PUBMED](#) | [CROSSREF](#)
36. Park J, Kim TH, Lee JS, et al. Prolonged PR interval predicts clinical recurrence of atrial fibrillation after catheter ablation. *J Am Heart Assoc* 2014;3:e001277.
[PUBMED](#) | [CROSSREF](#)
37. Park J, Joung B, Uhm JS, et al. High left atrial pressures are associated with advanced electroanatomical remodeling of left atrium and independent predictors for clinical recurrence of atrial fibrillation after catheter ablation. *Heart Rhythm* 2014;11:953-60.
[PUBMED](#) | [CROSSREF](#)
38. Kim IS, Kim TH, Yang PS, et al. Minimal energy requirement for external cardioversion and catheter ablation for long-standing persistent atrial fibrillation. *J Cardiol* 2017;69:162-8.
[PUBMED](#) | [CROSSREF](#)
39. Park JK, Lee JY, Yang PS, et al. Good responders to catheter ablation for long-standing persistent atrial fibrillation: clinical and genetic characteristics. *J Cardiol* 2017;69:584-90.
[PUBMED](#) | [CROSSREF](#)
40. Kang KW, Pak HN, Park J, et al. Additional linear ablation from the superior vena cava to right atrial septum after pulmonary vein isolation improves the clinical outcome in patients with paroxysmal atrial fibrillation: prospective randomized study. *Europace* 2014;16:1738-45.
[PUBMED](#) | [CROSSREF](#)
41. Lee KN, Roh SY, Baek YS, et al. Long-term clinical comparison of procedural end points after pulmonary vein isolation in paroxysmal atrial fibrillation: elimination of nonpulmonary vein triggers versus noninducibility. *Circ Arrhythm Electrophysiol* 2018;11:e005019.
[PUBMED](#) | [CROSSREF](#)
42. Kim TH, Park J, Uhm JS, et al. Challenging achievement of bidirectional block after linear ablation affects the rhythm outcome in patients with persistent atrial fibrillation. *J Am Heart Assoc* 2016;5:e003894.
[PUBMED](#) | [CROSSREF](#)
43. Yu HT, Shim J, Park J, et al. Pulmonary vein isolation alone versus additional linear ablation in patients with persistent atrial fibrillation converted to paroxysmal type with antiarrhythmic drug therapy: a multicenter, prospective, randomized study. *Circ Arrhythm Electrophysiol* 2017;10:e004915.
[PUBMED](#) | [CROSSREF](#)
44. Kim TH, Uhm JS, Kim JY, Joung B, Lee MH, Pak HN. Does additional electrogram-guided ablation after linear ablation reduce recurrence after catheter ablation for longstanding persistent atrial fibrillation? a prospective randomized study. *J Am Heart Assoc* 2017;6:e004811.
[PUBMED](#) | [CROSSREF](#)
45. Oral H, Pappone C, Chugh A, et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. *N Engl J Med* 2006;354:934-41.
[PUBMED](#) | [CROSSREF](#)

46. Chen SA, Hsieh MH, Tai CT, et al. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. *Circulation* 1999;100:1879-86.
[PUBMED](#) | [CROSSREF](#)
47. Pappone C, Santinelli V, Manguso F, et al. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. *Circulation* 2004;109:327-34.
[PUBMED](#) | [CROSSREF](#)
48. Krul SP, Driessen AH, van Boven WJ, et al. Thoracoscopic video-assisted pulmonary vein antrum isolation, ganglionated plexus ablation, and periprocedural confirmation of ablation lesions: first results of a hybrid surgical-electrophysiological approach for atrial fibrillation. *Circ Arrhythm Electrophysiol* 2011;4:262-70.
[PUBMED](#) | [CROSSREF](#)
49. Edgerton JR, Brinkman WT, Weaver T, et al. Pulmonary vein isolation and autonomic denervation for the management of paroxysmal atrial fibrillation by a minimally invasive surgical approach. *J Thorac Cardiovasc Surg* 2010;140:823-8.
[PUBMED](#) | [CROSSREF](#)
50. Oh S, Zhang Y, Bibevski S, Marrouche NF, Natale A, Mazgalev TN. Vagal denervation and atrial fibrillation inducibility: epicardial fat pad ablation does not have long-term effects. *Heart Rhythm* 2006;3:701-8.
[PUBMED](#) | [CROSSREF](#)
51. Schauerte P, Scherlag BJ, Pitha J, et al. Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation. *Circulation* 2000;102:2774-80.
[PUBMED](#) | [CROSSREF](#)
52. Haïssaguerre M, Sanders P, Hocini M, et al. Catheter ablation of long-lasting persistent atrial fibrillation: critical structures for termination. *J Cardiovasc Electrophysiol* 2005;16:1125-37.
[PUBMED](#) | [CROSSREF](#)
53. Haïssaguerre M, Hocini M, Sanders P, et al. Catheter ablation of long-lasting persistent atrial fibrillation: clinical outcome and mechanisms of subsequent arrhythmias. *J Cardiovasc Electrophysiol* 2005;16:1138-47.
[PUBMED](#) | [CROSSREF](#)
54. Lo LW, Lin YJ, Tsao HM, et al. The impact of left atrial size on long-term outcome of catheter ablation of chronic atrial fibrillation. *J Cardiovasc Electrophysiol* 2009;20:1211-6.
[PUBMED](#) | [CROSSREF](#)
55. Elayi CS, Di Biase L, Barrett C, et al. Atrial fibrillation termination as a procedural endpoint during ablation in long-standing persistent atrial fibrillation. *Heart Rhythm* 2010;7:1216-23.
[PUBMED](#) | [CROSSREF](#)
56. O'Neill MD, Wright M, Knecht S, et al. Long-term follow-up of persistent atrial fibrillation ablation using termination as a procedural endpoint. *Eur Heart J* 2009;30:1105-12.
[PUBMED](#) | [CROSSREF](#)
57. Knecht S, Hocini M, Wright M, et al. Left atrial linear lesions are required for successful treatment of persistent atrial fibrillation. *Eur Heart J* 2008;29:2359-66.
[PUBMED](#) | [CROSSREF](#)
58. Wynn GJ, Das M, Bonnett LJ, Panikker S, Wong T, Gupta D. Efficacy of catheter ablation for persistent atrial fibrillation: a systematic review and meta-analysis of evidence from randomized and nonrandomized controlled trials. *Circ Arrhythm Electrophysiol* 2014;7:841-52.
[PUBMED](#) | [CROSSREF](#)
59. Hocini M, Jaïs P, Sanders P, et al. Techniques, evaluation, and consequences of linear block at the left atrial roof in paroxysmal atrial fibrillation: a prospective randomized study. *Circulation* 2005;112:3688-96.
[PUBMED](#) | [CROSSREF](#)
60. Jaïs P, Hocini M, Hsu LF, et al. Technique and results of linear ablation at the mitral isthmus. *Circulation* 2004;110:2996-3002.
[PUBMED](#) | [CROSSREF](#)
61. Jaïs P, Hocini M, O'Neill MD, et al. How to perform linear lesions. *Heart Rhythm* 2007;4:803-9.
[PUBMED](#) | [CROSSREF](#)
62. Konings KT, Kirchhof CJ, Smeets JR, Wellens HJ, Penn OC, Allesie MA. High-density mapping of electrically induced atrial fibrillation in humans. *Circulation* 1994;89:1665-80.
[PUBMED](#) | [CROSSREF](#)
63. Nademanee K, McKenzie J, Kosar E, et al. A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. *J Am Coll Cardiol* 2004;43:2044-53.
[PUBMED](#) | [CROSSREF](#)

64. Konings KT, Smeets JL, Penn OC, Wellens HJ, Allessie MA. Configuration of unipolar atrial electrograms during electrically induced atrial fibrillation in humans. *Circulation* 1997;95:1231-41.
[PUBMED](#) | [CROSSREF](#)
65. Lo LW, Lin YJ, Tsao HM, et al. Characteristics of complex fractionated electrograms in nonpulmonary vein ectopy initiating atrial fibrillation/atrial tachycardia. *J Cardiovasc Electrophysiol* 2009;20:1305-12.
[PUBMED](#) | [CROSSREF](#)
66. Ho SY, Sanchez-Quintana D, Cabrera JA, Anderson RH. Anatomy of the left atrium: implications for radiofrequency ablation of atrial fibrillation. *J Cardiovasc Electrophysiol* 1999;10:1525-33.
[PUBMED](#)
67. Teh AW, Kalman JM, Kistler PM, et al. Prevalence of fractionated electrograms in the coronary sinus: comparison between patients with persistent or paroxysmal atrial fibrillation and a control population. *Heart Rhythm* 2010;7:1200-4.
[PUBMED](#) | [CROSSREF](#)
68. Jacquemet V, Henriquez CS. Genesis of complex fractionated atrial electrograms in zones of slow conduction: a computer model of microfibrosis. *Heart Rhythm* 2009;6:803-10.
[PUBMED](#) | [CROSSREF](#)
69. Jadidi AS, Duncan E, Miyazaki S, et al. Functional nature of electrogram fractionation demonstrated by left atrial high-density mapping. *Circ Arrhythm Electrophysiol* 2012;5:32-42.
[PUBMED](#) | [CROSSREF](#)
70. Spach MS, Dolber PC. Relating extracellular potentials and their derivatives to anisotropic propagation at a microscopic level in human cardiac muscle. Evidence for electrical uncoupling of side-to-side fiber connections with increasing age. *Circ Res* 1986;58:356-71.
[PUBMED](#) | [CROSSREF](#)
71. Ortiz J, Niwano S, Abe H, Rudy Y, Johnson NJ, Waldo AL. Mapping the conversion of atrial flutter to atrial fibrillation and atrial fibrillation to atrial flutter. Insights into mechanisms. *Circ Res* 1994;74:882-94.
[PUBMED](#) | [CROSSREF](#)
72. Brugada J, Mont L, Boersma L, Kirchhof C, Allessie MA. Differential effects of heptanol, potassium, and tetrodotoxin on reentrant ventricular tachycardia around a fixed obstacle in anisotropic myocardium. *Circulation* 1991;84:1307-18.
[PUBMED](#) | [CROSSREF](#)
73. Park JH, Pak HN, Kim SK, et al. Electrophysiologic characteristics of complex fractionated atrial electrograms in patients with atrial fibrillation. *J Cardiovasc Electrophysiol* 2009;20:266-72.
[PUBMED](#) | [CROSSREF](#)
74. Park JH, Park SW, Kim JY, et al. Characteristics of complex fractionated atrial electrogram in the electroanatomically remodeled left atrium of patients with atrial fibrillation. *Circ J* 2010;74:1557-63.
[PUBMED](#) | [CROSSREF](#)
75. Oral H, Chugh A, Yoshida K, et al. A randomized assessment of the incremental role of ablation of complex fractionated atrial electrograms after antral pulmonary vein isolation for long-lasting persistent atrial fibrillation. *J Am Coll Cardiol* 2009;53:782-9.
[PUBMED](#) | [CROSSREF](#)
76. Di Biase L, Santangeli P, Natale A. How to ablate long-standing persistent atrial fibrillation? *Curr Opin Cardiol* 2013;28:26-35.
[PUBMED](#)
77. Song JS, Kim J, Lim B, et al. Pro-arrhythmogenic effects of heterogeneous tissue curvature- a suggestion for role of left atrial appendage in atrial fibrillation. *Circ J*. 2018 [Epub ahead of print].
[PUBMED](#) | [CROSSREF](#)
78. Saksena S, Skadsberg ND, Rao HB, Filipecki A. Batrial and three-dimensional mapping of spontaneous atrial arrhythmias in patients with refractory atrial fibrillation. *J Cardiovasc Electrophysiol* 2005;16:494-504.
[PUBMED](#) | [CROSSREF](#)
79. Nitta T, Ishii Y, Miyagi Y, Ohmori H, Sakamoto S, Tanaka S. Concurrent multiple left atrial focal activations with fibrillatory conduction and right atrial focal or reentrant activation as the mechanism in atrial fibrillation. *J Thorac Cardiovasc Surg* 2004;127:770-8.
[PUBMED](#) | [CROSSREF](#)
80. Kim YH. Catheter ablation of longstanding persistent atrial fibrillation. Are we on the right path? *Circ J* 2012;76:1299-306.
[PUBMED](#) | [CROSSREF](#)
81. Oral H, Chugh A, Good E, et al. Randomized evaluation of right atrial ablation after left atrial ablation of complex fractionated atrial electrograms for long-lasting persistent atrial fibrillation. *Circ Arrhythm Electrophysiol* 2008;1:6-13.
[PUBMED](#) | [CROSSREF](#)

82. Calò L, Lamberti F, Loricchio ML, et al. Left atrial ablation versus biatrial ablation for persistent and permanent atrial fibrillation: a prospective and randomized study. *J Am Coll Cardiol* 2006;47:2504-12.
[PUBMED](#) | [CROSSREF](#)
83. Narayan SM, Krummen DE, Shivkumar K, Clopton P, Rappel WJ, Miller JM. Treatment of atrial fibrillation by the ablation of localized sources: CONFIRM (conventional ablation for atrial fibrillation with or without focal impulse and rotor modulation) trial. *J Am Coll Cardiol* 2012;60:628-36.
[PUBMED](#) | [CROSSREF](#)
84. Pandit SV, Jalife J. Rotors and the dynamics of cardiac fibrillation. *Circ Res* 2013;112:849-62.
[PUBMED](#) | [CROSSREF](#)
85. Gray RA, Jalife J, Panfilov AV, et al. Mechanisms of cardiac fibrillation. *Science* 1995;270:1222-3.
[PUBMED](#) | [CROSSREF](#)
86. Narayan SM, Baykaner T, Clopton P, et al. Ablation of rotor and focal sources reduces late recurrence of atrial fibrillation compared with trigger ablation alone: extended follow-up of the CONFIRM trial (conventional ablation for atrial fibrillation with or without focal impulse and rotor modulation). *J Am Coll Cardiol* 2014;63:1761-8.
[PUBMED](#) | [CROSSREF](#)
87. Buch E, Share M, Tung R, et al. Long-term clinical outcomes of focal impulse and rotor modulation for treatment of atrial fibrillation: a multicenter experience. *Heart Rhythm* 2016;13:636-41.
[PUBMED](#) | [CROSSREF](#)
88. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). *Europace* 2010;12:1360-420.
[PUBMED](#) | [CROSSREF](#)
89. Beyer E, Lee R, Lam BK. Point: minimally invasive bipolar radiofrequency ablation of lone atrial fibrillation: early multicenter results. *J Thorac Cardiovasc Surg* 2009;137:521-6.
[PUBMED](#) | [CROSSREF](#)
90. Yilmaz A, Geuzebroek GS, Van Putte BP, et al. Completely thoracoscopic pulmonary vein isolation with ganglionic plexus ablation and left atrial appendage amputation for treatment of atrial fibrillation. *Eur J Cardiothorac Surg* 2010;38:356-60.
[PUBMED](#) | [CROSSREF](#)
91. McClelland JH, Duke D, Reddy R. Preliminary results of a limited thoracotomy: new approach to treat atrial fibrillation. *J Cardiovasc Electrophysiol* 2007;18:1289-95.
[PUBMED](#) | [CROSSREF](#)
92. Boersma LV, Castella M, van Boven W, et al. Atrial fibrillation catheter ablation versus surgical ablation treatment (FAST): a 2-center randomized clinical trial. *Circulation* 2012;125:23-30.
[PUBMED](#) | [CROSSREF](#)
93. Berruezo A, Tamborero D, Mont L, et al. Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. *Eur Heart J* 2007;28:836-41.
[PUBMED](#) | [CROSSREF](#)
94. Adiyaman A, Buist TJ, Beukema RJ, et al. Randomized controlled trial of surgical versus catheter ablation for paroxysmal and early persistent atrial fibrillation. *Circ Arrhythm Electrophysiol* 2018;11:e006182.
[PUBMED](#) | [CROSSREF](#)
95. Canpolat U, Özeke Ö, Çay S, Topaloğlu S, Aras D. Worsened diastology after radiofrequency catheter ablation in AF patients: more touches more stiff left atrium. *Int J Cardiol* 2013;168:4801-2.
[PUBMED](#) | [CROSSREF](#)
96. Gibson DN, Di Biase L, Mohanty P, et al. Stiff left atrial syndrome after catheter ablation for atrial fibrillation: clinical characterization, prevalence, and predictors. *Heart Rhythm* 2011;8:1364-71.
[PUBMED](#) | [CROSSREF](#)
97. Marrouche NF, Wilber D, Hindricks G, et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. *JAMA* 2014;311:498-506.
[PUBMED](#) | [CROSSREF](#)
98. Shim J, Joung B, Park JH, Uhm JS, Lee MH, Pak HN. Long duration of radiofrequency energy delivery is an independent predictor of clinical recurrence after catheter ablation of atrial fibrillation: over 500 cases experience. *Int J Cardiol* 2013;167:2667-72.
[PUBMED](#) | [CROSSREF](#)
99. Husser D, Adams V, Piorkowski C, Hindricks G, Bollmann A. Chromosome 4q25 variants and atrial fibrillation recurrence after catheter ablation. *J Am Coll Cardiol* 2010;55:747-53.
[PUBMED](#) | [CROSSREF](#)
100. Gudbjartsson DF, Arnar DO, Helgadóttir A, et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. *Nature* 2007;448:353-7.
[PUBMED](#) | [CROSSREF](#)

101. Hwang M, Kwon SS, Wi J, et al. Virtual ablation for atrial fibrillation in personalized in-silico three-dimensional left atrial modeling: comparison with clinical catheter ablation. *Prog Biophys Mol Biol* 2014;116:40-7.
[PUBMED](#) | [CROSSREF](#)
102. Ruchat P, Virag N, Dang L, Schlaepfer J, Pruvot E, Kappenberger L. A biophysical model of atrial fibrillation ablation: what can a surgeon learn from a computer model? *Europace* 2007;9 Suppl 6:vi71-6.
[PUBMED](#) | [CROSSREF](#)